市場調査レポート

商品コード

1513318

ワクチン市場：技術タイプ別、適応症別、エンドユーザー別：世界の機会分析と産業予測、2024年～2035年

Vaccines Market By Technology Type, By Indication, By End User : Global Opportunity Analysis and Industry Forecast, 2024-2035

出版日: 2024年04月01日
発行: Allied Market Research
ページ情報: 英文 350 Pages
納期: 2～3営業日

価格

PDF (Business License)

USD 6,090 906,801円

レポートPDFを1名がご利用いただけるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は5回まで可能です。 2名以上でご利用の場合、追加料金を支払う事によりユーザーを最大５名まで追加する事が可能です。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 10,500 1,563,450円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=148.90円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

ワクチン市場は2023年に432億米ドルと評価され、2024年から2035年までのCAGRは6.4%を記録し、2035年には907億米ドルに達すると予測されています。ワクチンは、特定の感染症に対する免疫を提供する生物学的製剤です。ワクチンには通常、病原体、その毒素、表面タンパク質の弱毒化または不活性化したものが含まれており、免疫系を刺激して病原体を認識・記憶させる。ワクチン接種を受けると、免疫系は抗体を産生し、その病原体に特異的な免疫細胞を活性化することで反応します。これにより体内に防御機構が形成され、後に実際の感染症病原体にさらされた場合でも、免疫系が速やかに病原体を認識して破壊し、病気の重症化を予防または軽減することができます。ワクチンは、歴史を通じて多くの致命的な病気の制圧と撲滅に役立っており、現代医学における最も重要な進歩のひとつとなっています。

ワクチン市場の成長は、主にインフルエンザ、肺炎球菌性疾患、HPV、その他の感染症など、ワクチン投与を必要とする疾患の有病率の上昇によってもたらされます。例えば、2023年に米国疾病予防管理センター（CDC）は、3,100万人がインフルエンザに罹患したと推定しています。また、ワクチンの研究開発、製造インフラ、公的予防接種プログラムに対する政府の投資は、ワクチン市場に大きな影響を与えます。官民パートナーシップ、助成金、税制優遇措置、規制の枠組みはワクチン開発のインセンティブとなり、安全性、有効性、品質基準を確保します。米国食品医薬品局（FDA）、欧州医薬品庁（EMA）、世界保健機関（WHO）などの規制機関は、ワクチンの評価と認可において極めて重要な役割を担っており、市場参入と採用に影響を与えています。しかし、高額な開発費、複雑な製造工程、厳しい規制要件がワクチンの高価格の一因となっており、特に中低所得国（LMICs）における購入可能な価格には限界があるため、市場の成長を抑制する可能性があります。対照的に、バイオテクノロジー、ゲノム科学、免疫学の進歩が進んでいるため、新しく改良されたワクチンの開発を通じて疾病の予防と管理を拡大する機会があります。新たな感染症、抗菌剤耐性、再興病原体は、満たされていない医療ニーズに対応し、公衆衛生の脅威を軽減するための革新的なワクチンソリューションの必要性を強調しています。ワクチン市場は、技術タイプ、適応症、エンドユーザー、地域によって区分されます。技術タイプ別では、組換え・結合型ワクチン、弱毒生ワクチン、不活化ワクチン、トキソイドワクチン、その他に分類されます。適応症別では、肺炎球菌感染症、インフルエンザ、ヒト乳頭腫ウイルス、髄膜炎菌感染症、ロタウイルス、水痘、麻疹・おたふく風邪・風疹、ジフテリア・百日咳・破傷風（DTP）、ポリオ、肝炎、その他の適応症に分類されます。エンドユーザーによって、市場は小児、成人、旅行者に分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州地域）、アジア太平洋地域（日本、中国、オーストラリア、インド、韓国、その他アジア太平洋地域）、南米地域（ブラジル、サウジアラビア、アフリカ、その他南米地域）で分析されます。世界のワクチン市場で事業を展開する主な主要企業は、Merck &Co., Inc.、ファイザー、サノフィ、Serum Institute of India Pvt. Ltd.、Bavarian Nordic、CSL Limited、Emergent Bio Solutions Inc.、GlaxoSmithKline plc.、Zhi Fei Biological、Bharat Biotechです。市場で事業を展開する主要企業は、製品ポートフォリオを拡大するための主要戦略として、臨床試験、製品上市、製品承認、事業拡大を採用している。

利害関係者にとっての主なメリット

当レポートでは、2023年から2035年にかけてのワクチン市場分析の市場セグメント、現在の動向、推定・動向、ダイナミクスを定量的に分析し、ワクチン市場の実勢機会を明らかにします。
市場促進要因、市場抑制要因、市場機会に関連する情報とともに市場調査を提供します。
ポーターのファイブフォース分析では、利害関係者が利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるよう、バイヤーとサプライヤーの潜在力を強調します。
ワクチン市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解します。
本レポートには、地域別および世界のワクチン市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析が含まれています。その他の特典は以下の通りです：
四半期ごとの最新情報および*（法人向けライセンスでのみご利用いただけます。）
購入前または購入後に、ご希望の企業プロファイルを5社追加で無料アップデート。
5ユーザー・ライセンスおよびエンタープライズ・ユーザー・ライセンス購入の場合、次期バージョンを無料で提供。
アナリストによる16時間のサポート*（購入後、レポートのレビューで追加データ要件が見つかった場合、質問や販売後の問い合わせを解決するためにアナリストによる16時間のサポートを受けることができます）
15%の無料カスタマイズ*（レポートの調査範囲またはセグメントがお客様の要件に一致しない場合、15%は3営業日の無料作業に相当します。）
5ユーザーライセンスおよびエンタープライズユーザーライセンスの無料データパック。（エクセル版レポート）
レポートが6～12ヶ月以上前の場合、更新レポートを無料で提供。
24時間優先対応*。
業界の最新情報とホワイトペーパーを無料で提供本レポートのカスタマイズが可能（別途費用とスケジュールがかかります。）
規制ガイドライン
顧客の関心に応じた追加企業プロファイル
国別または地域別の追加分析-市場規模と予測
企業プロファイルの拡張リスト
過去の市場データ
主要プレーヤーの詳細（所在地、連絡先、サプライヤー／ベンダーネットワークなどを含む、エクセル形式）

概要
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- イタリア
- スペイン
- その他
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- その他
ラテンアメリカ・中東・アフリカ
- ブラジル
- サウジアラビア
- 南アフリカ
- その他

第8章競争情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング、2023年

第9章企業プロファイル

CSL Limited
Emergent Bio Solutions Inc.
GlaxoSmithKline Plc.
Merck & Co., Inc.
Pfizer
Sanofi
Serum Institute of India Pvt. Ltd.
Bavarian Nordic
Zhi Fei Biological
Bharat Biotech

図表

LIST OF TABLES

TABLE 01. GLOBAL VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 02. VACCINES MARKET FOR RECOMBINANT AND CONJUGATE VACCINES, BY REGION, 2023-2035 ($MILLION)
TABLE 03. VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY REGION, 2023-2035 ($MILLION)
TABLE 04. VACCINES MARKET FOR INACTIVATED VACCINES, BY REGION, 2023-2035 ($MILLION)
TABLE 05. VACCINES MARKET FOR TOXOID VACCINES, BY REGION, 2023-2035 ($MILLION)
TABLE 06. VACCINES MARKET FOR OTHERS, BY REGION, 2023-2035 ($MILLION)
TABLE 07. GLOBAL VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 08. VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2023-2035 ($MILLION)
TABLE 09. VACCINES MARKET FOR INFLUENZA, BY REGION, 2023-2035 ($MILLION)
TABLE 10. VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY REGION, 2023-2035 ($MILLION)
TABLE 11. VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY REGION, 2023-2035 ($MILLION)
TABLE 12. VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2023-2035 ($MILLION)
TABLE 13. VACCINES MARKET FOR VARICELLA, BY REGION, 2023-2035 ($MILLION)
TABLE 14. VACCINES MARKET FOR MEASLES, MUMPS, AND RUBELLA, BY REGION, 2023-2035 ($MILLION)
TABLE 15. VACCINES MARKET FOR DIPHTHERIA, PERTUSSIS, AND TETANUS (DTP), BY REGION, 2023-2035 ($MILLION)
TABLE 16. VACCINES MARKET FOR POLIO, BY REGION, 2023-2035 ($MILLION)
TABLE 17. VACCINES MARKET FOR HEPATITIS, BY REGION, 2023-2035 ($MILLION)
TABLE 18. VACCINES MARKET FOR OTHER INDICATIONS, BY REGION, 2023-2035 ($MILLION)
TABLE 19. GLOBAL VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 20. VACCINES MARKET FOR PEDIATRIC, BY REGION, 2023-2035 ($MILLION)
TABLE 21. VACCINES MARKET FOR ADULTS, BY REGION, 2023-2035 ($MILLION)
TABLE 22. VACCINES MARKET FOR TRAVELERS, BY REGION, 2023-2035 ($MILLION)
TABLE 23. VACCINES MARKET, BY REGION, 2023-2035 ($MILLION)
TABLE 24. NORTH AMERICA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 25. NORTH AMERICA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 26. NORTH AMERICA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 27. NORTH AMERICA VACCINES MARKET, BY COUNTRY, 2023-2035 ($MILLION)
TABLE 28. U.S. VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 29. U.S. VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 30. U.S. VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 31. CANADA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 32. CANADA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 33. CANADA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 34. MEXICO VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 35. MEXICO VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 36. MEXICO VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 37. EUROPE VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 38. EUROPE VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 39. EUROPE VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 40. EUROPE VACCINES MARKET, BY COUNTRY, 2023-2035 ($MILLION)
TABLE 41. GERMANY VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 42. GERMANY VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 43. GERMANY VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 44. FRANCE VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 45. FRANCE VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 46. FRANCE VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 47. UK VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 48. UK VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 49. UK VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 50. ITALY VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 51. ITALY VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 52. ITALY VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 53. SPAIN VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 54. SPAIN VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 55. SPAIN VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 56. REST OF EUROPE VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 57. REST OF EUROPE VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 58. REST OF EUROPE VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 59. ASIA-PACIFIC VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 60. ASIA-PACIFIC VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 61. ASIA-PACIFIC VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 62. ASIA-PACIFIC VACCINES MARKET, BY COUNTRY, 2023-2035 ($MILLION)
TABLE 63. JAPAN VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 64. JAPAN VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 65. JAPAN VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 66. CHINA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 67. CHINA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 68. CHINA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 69. INDIA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 70. INDIA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 71. INDIA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 72. AUSTRALIA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 73. AUSTRALIA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 74. AUSTRALIA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 75. SOUTH KOREA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 76. SOUTH KOREA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 77. SOUTH KOREA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 78. REST OF ASIA-PACIFIC VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 79. REST OF ASIA-PACIFIC VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 80. REST OF ASIA-PACIFIC VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 81. LAMEA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 82. LAMEA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 83. LAMEA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 84. LAMEA VACCINES MARKET, BY COUNTRY, 2023-2035 ($MILLION)
TABLE 85. BRAZIL VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 86. BRAZIL VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 87. BRAZIL VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 88. SAUDI ARABIA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 89. SAUDI ARABIA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 90. SAUDI ARABIA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 91. SOUTH AFRICA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 92. SOUTH AFRICA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 93. SOUTH AFRICA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 94. REST OF LAMEA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 95. REST OF LAMEA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 96. REST OF LAMEA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 97. CSL LIMITED: KEY EXECUTIVES
TABLE 98. CSL LIMITED: COMPANY SNAPSHOT
TABLE 99. CSL LIMITED: PRODUCT SEGMENTS
TABLE 100. CSL LIMITED: SERVICE SEGMENTS
TABLE 101. CSL LIMITED: PRODUCT PORTFOLIO
TABLE 102. CSL LIMITED: KEY STRATEGIES
TABLE 103. EMERGENT BIO SOLUTIONS INC.: KEY EXECUTIVES
TABLE 104. EMERGENT BIO SOLUTIONS INC.: COMPANY SNAPSHOT
TABLE 105. EMERGENT BIO SOLUTIONS INC.: PRODUCT SEGMENTS
TABLE 106. EMERGENT BIO SOLUTIONS INC.: SERVICE SEGMENTS
TABLE 107. EMERGENT BIO SOLUTIONS INC.: PRODUCT PORTFOLIO
TABLE 108. EMERGENT BIO SOLUTIONS INC.: KEY STRATEGIES
TABLE 109. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
TABLE 110. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
TABLE 111. GLAXOSMITHKLINE PLC.: PRODUCT SEGMENTS
TABLE 112. GLAXOSMITHKLINE PLC.: SERVICE SEGMENTS
TABLE 113. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 114. GLAXOSMITHKLINE PLC.: KEY STRATEGIES
TABLE 115. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 116. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 117. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 118. MERCK & CO., INC.: SERVICE SEGMENTS
TABLE 119. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 120. MERCK & CO., INC.: KEY STRATEGIES
TABLE 121. PFIZER: KEY EXECUTIVES
TABLE 122. PFIZER: COMPANY SNAPSHOT
TABLE 123. PFIZER: PRODUCT SEGMENTS
TABLE 124. PFIZER: SERVICE SEGMENTS
TABLE 125. PFIZER: PRODUCT PORTFOLIO
TABLE 126. PFIZER: KEY STRATEGIES
TABLE 127. SANOFI: KEY EXECUTIVES
TABLE 128. SANOFI: COMPANY SNAPSHOT
TABLE 129. SANOFI: PRODUCT SEGMENTS
TABLE 130. SANOFI: SERVICE SEGMENTS
TABLE 131. SANOFI: PRODUCT PORTFOLIO
TABLE 132. SANOFI: KEY STRATEGIES
TABLE 133. SERUM INSTITUTE OF INDIA PVT. LTD.: KEY EXECUTIVES
TABLE 134. SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY SNAPSHOT
TABLE 135. SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT SEGMENTS
TABLE 136. SERUM INSTITUTE OF INDIA PVT. LTD.: SERVICE SEGMENTS
TABLE 137. SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT PORTFOLIO
TABLE 138. SERUM INSTITUTE OF INDIA PVT. LTD.: KEY STRATEGIES
TABLE 139. BAVARIAN NORDIC: KEY EXECUTIVES
TABLE 140. BAVARIAN NORDIC: COMPANY SNAPSHOT
TABLE 141. BAVARIAN NORDIC: PRODUCT SEGMENTS
TABLE 142. BAVARIAN NORDIC: SERVICE SEGMENTS
TABLE 143. BAVARIAN NORDIC: PRODUCT PORTFOLIO
TABLE 144. BAVARIAN NORDIC: KEY STRATEGIES
TABLE 145. ZHI FEI BIOLOGICAL: KEY EXECUTIVES
TABLE 146. ZHI FEI BIOLOGICAL: COMPANY SNAPSHOT
TABLE 147. ZHI FEI BIOLOGICAL: PRODUCT SEGMENTS
TABLE 148. ZHI FEI BIOLOGICAL: SERVICE SEGMENTS
TABLE 149. ZHI FEI BIOLOGICAL: PRODUCT PORTFOLIO
TABLE 150. ZHI FEI BIOLOGICAL: KEY STRATEGIES
TABLE 151. BHARAT BIOTECH: KEY EXECUTIVES
TABLE 152. BHARAT BIOTECH: COMPANY SNAPSHOT
TABLE 153. BHARAT BIOTECH: PRODUCT SEGMENTS
TABLE 154. BHARAT BIOTECH: SERVICE SEGMENTS
TABLE 155. BHARAT BIOTECH: PRODUCT PORTFOLIO
TABLE 156. BHARAT BIOTECH: KEY STRATEGIES

LIST OF FIGURES

FIGURE 01. VACCINES MARKET, 2023-2035
FIGURE 02. SEGMENTATION OF VACCINES MARKET,2023-2035
FIGURE 03. TOP IMPACTING FACTORS IN VACCINES MARKET
FIGURE 04. TOP INVESTMENT POCKETS IN VACCINES MARKET (2024-2035)
FIGURE 05. BARGAINING POWER OF SUPPLIERS
FIGURE 06. BARGAINING POWER OF BUYERS
FIGURE 07. THREAT OF SUBSTITUTION
FIGURE 08. THREAT OF SUBSTITUTION
FIGURE 09. COMPETITIVE RIVALRY
FIGURE 10. GLOBAL VACCINES MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. VACCINES MARKET, BY TECHNOLOGY TYPE, 2023 AND 2035(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR RECOMBINANT AND CONJUGATE VACCINES, BY COUNTRY 2023 AND 2035(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY 2023 AND 2035(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR INACTIVATED VACCINES, BY COUNTRY 2023 AND 2035(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY 2023 AND 2035(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR OTHERS, BY COUNTRY 2023 AND 2035(%)
FIGURE 17. VACCINES MARKET, BY INDICATION, 2023 AND 2035(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY 2023 AND 2035(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR INFLUENZA, BY COUNTRY 2023 AND 2035(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY COUNTRY 2023 AND 2035(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY 2023 AND 2035(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY 2023 AND 2035(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR VARICELLA, BY COUNTRY 2023 AND 2035(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR MEASLES, MUMPS, AND RUBELLA, BY COUNTRY 2023 AND 2035(%)
FIGURE 25. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR DIPHTHERIA, PERTUSSIS, AND TETANUS (DTP), BY COUNTRY 2023 AND 2035(%)
FIGURE 26. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR POLIO, BY COUNTRY 2023 AND 2035(%)
FIGURE 27. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR HEPATITIS, BY COUNTRY 2023 AND 2035(%)
FIGURE 28. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY 2023 AND 2035(%)
FIGURE 29. VACCINES MARKET, BY END USER, 2023 AND 2035(%)
FIGURE 30. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR PEDIATRIC, BY COUNTRY 2023 AND 2035(%)
FIGURE 31. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR ADULTS, BY COUNTRY 2023 AND 2035(%)
FIGURE 32. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR TRAVELERS, BY COUNTRY 2023 AND 2035(%)
FIGURE 33. VACCINES MARKET BY REGION, 2023 AND 2035(%)
FIGURE 34. U.S. VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 35. CANADA VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 36. MEXICO VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 37. GERMANY VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 38. FRANCE VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 39. UK VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 40. ITALY VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 41. SPAIN VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 42. REST OF EUROPE VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 43. JAPAN VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 44. CHINA VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 45. INDIA VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 46. AUSTRALIA VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 47. SOUTH KOREA VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 48. REST OF ASIA-PACIFIC VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 49. BRAZIL VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 50. SAUDI ARABIA VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 51. SOUTH AFRICA VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 52. REST OF LAMEA VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 53. TOP WINNING STRATEGIES, BY YEAR
FIGURE 54. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 55. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 56. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 57. COMPETITIVE DASHBOARD
FIGURE 58. COMPETITIVE HEATMAP: VACCINES MARKET
FIGURE 59. TOP PLAYER POSITIONING, 2023

Product Code: A00168

The vaccine market was valued at $43.2 billion in 2023 and is projected to reach $90.7 billion by 2035, registering a CAGR of 6.4% from 2024 to 2035. A vaccine is a biological preparation that provides immunity to a particular infectious disease. It typically contains weakened or inactive forms of the pathogen, its toxins, or surface proteins, which stimulate the immune system to recognize and remember the pathogen. When people are vaccinated, their immune system responds by producing antibodies and activating immune cells specific to that pathogen. This creates a defense mechanism within the body, so if a person is later exposed to the actual infectious agent, the immune system can quickly recognize and destroy it, preventing or reducing the severity of the disease. Vaccines have been instrumental in controlling and eradicating many deadly diseases throughout history, making them one of the most significant advancements in modern medicine.

The growth of the vaccine market is primarily driven by rise in prevalence of diseases, such as influenza, pneumococcal disease, HPV, and other infections, requiring administration of vaccines. For instance, in 2023, Centers for Disease Control and Prevention (CDC) estimated that 31 million people were sick with flu. In addition, government investment in vaccine research and development, manufacturing infrastructure, and public immunization programs significantly impacts the vaccine market. Public-private partnerships, grants, tax incentives, and regulatory frameworks incentivize vaccine development and ensure safety, efficacy, and quality standards. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO), play pivotal roles in evaluating and approving vaccines for licensure, which influences market access and adoption. However, the high development costs, complex manufacturing processes, and stringent regulatory requirements contribute to the high prices of vaccines, limiting affordability, especially in low- and middle-income countries (LMICs) which may restrain the market growth. In contrast, due to ongoing advancements in biotechnology, genomics, and immunology, there is an opportunity to expand disease prevention and control through the development of new and improved vaccines. Emerging infectious diseases, antimicrobial resistance, and re-emerging pathogens underscore the need for innovative vaccine solutions to address unmet medical needs and mitigate public health threats. The vaccine market is segmented on the basis of technology type, indication, end user, and region. By technology type, the market is categorized into recombinant and conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and others. As per indication, the market is divided into pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella, measles, mumps, and rubella, diphtheria, pertussis, and tetanus (DTP), polio, hepatitis, and other indications. Depending on end user, the market is categorized into pediatric, adults, and travelers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA). Major key players that operate in the global vaccine market are Merck & Co., Inc., Pfizer, Sanofi, Serum Institute of India Pvt. Ltd., Bavarian Nordic, CSL Limited, Emergent Bio Solutions Inc., GlaxoSmithKline plc., Zhi Fei Biological, and Bharat Biotech. The key players operating in the market have adopted clinical trial, product launch, product approval, and expansion as their key strategies to expand their product portfolio.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vaccines market analysis from 2023 to 2035 to identify the prevailing vaccines market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the vaccines market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global vaccines market trends, key players, market segments, application areas, and market growth strategies. Additional benefits you will get with this purchase are:
Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers. Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Technology Type

Inactivated Vaccines
Toxoid Vaccines
Others
Recombinant and Conjugate Vaccines
Live Attenuated Vaccines

By Indication

Pneumococcal Disease
Influenza
Human Papilloma Virus
Meningococcal Disease
Rotavirus
Varicella
Measles, Mumps, and Rubella
Diphtheria, Pertussis, and Tetanus (DTP)
Polio
Hepatitis
Other Indications

By End User

Pediatric
Adults
Travelers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

CSL Limited
Emergent Bi

Solutions Inc.

GlaxoSmithKline Plc.
Merck & Co., Inc.
Pfizer
Sanofi
Serum Institute of India Pvt. Ltd.
Bavarian Nordic
Zhi Fei Biological
Bharat Biotech

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: VACCINES MARKET, BY TECHNOLOGY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Recombinant and Conjugate Vaccines
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Live Attenuated Vaccines
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Inactivated Vaccines
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Toxoid Vaccines
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
4.6. Others
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country

CHAPTER 5: VACCINES MARKET, BY INDICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Pneumococcal Disease
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Influenza
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Human Papilloma Virus
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Meningococcal Disease
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country
5.6. Rotavirus
- 5.6.1. Key market trends, growth factors and opportunities
- 5.6.2. Market size and forecast, by region
- 5.6.3. Market share analysis by country
5.7. Varicella
- 5.7.1. Key market trends, growth factors and opportunities
- 5.7.2. Market size and forecast, by region
- 5.7.3. Market share analysis by country
5.8. Measles, Mumps, and Rubella
- 5.8.1. Key market trends, growth factors and opportunities
- 5.8.2. Market size and forecast, by region
- 5.8.3. Market share analysis by country
5.9. Diphtheria, Pertussis, and Tetanus (DTP)
- 5.9.1. Key market trends, growth factors and opportunities
- 5.9.2. Market size and forecast, by region
- 5.9.3. Market share analysis by country
5.10. Polio
- 5.10.1. Key market trends, growth factors and opportunities
- 5.10.2. Market size and forecast, by region
- 5.10.3. Market share analysis by country
5.11. Hepatitis
- 5.11.1. Key market trends, growth factors and opportunities
- 5.11.2. Market size and forecast, by region
- 5.11.3. Market share analysis by country
5.12. Other Indications
- 5.12.1. Key market trends, growth factors and opportunities
- 5.12.2. Market size and forecast, by region
- 5.12.3. Market share analysis by country

CHAPTER 6: VACCINES MARKET, BY END USER

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Pediatric
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Adults
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Travelers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: VACCINES MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Technology Type
- 7.2.3. Market size and forecast, by Indication
- 7.2.4. Market size and forecast, by End User
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Technology Type
  - 7.2.5.1.2. Market size and forecast, by Indication
  - 7.2.5.1.3. Market size and forecast, by End User
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Technology Type
  - 7.2.5.2.2. Market size and forecast, by Indication
  - 7.2.5.2.3. Market size and forecast, by End User
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Technology Type
  - 7.2.5.3.2. Market size and forecast, by Indication
  - 7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Technology Type
- 7.3.3. Market size and forecast, by Indication
- 7.3.4. Market size and forecast, by End User
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Market size and forecast, by Technology Type
  - 7.3.5.1.2. Market size and forecast, by Indication
  - 7.3.5.1.3. Market size and forecast, by End User
  - 7.3.5.2. France
  - 7.3.5.3.2. Market size and forecast, by Indication
  - 7.3.5.3.3. Market size and forecast, by End User
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Technology Type
  - 7.3.5.4.2. Market size and forecast, by Indication
  - 7.3.5.4.3. Market size and forecast, by End User
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Technology Type
  - 7.3.5.5.2. Market size and forecast, by Indication
  - 7.3.5.5.3. Market size and forecast, by End User
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Technology Type
  - 7.3.5.6.2. Market size and forecast, by Indication
  - 7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Technology Type
- 7.4.3. Market size and forecast, by Indication
- 7.4.4. Market size and forecast, by End User
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Technology Type
  - 7.4.5.1.2. Market size and forecast, by Indication
  - 7.4.5.1.3. Market size and forecast, by End User
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Technology Type
  - 7.4.5.2.2. Market size and forecast, by Indication
  - 7.4.5.2.3. Market size and forecast, by End User
  - 7.4.5.3. India
  - 7.4.5.3.1. Market size and forecast, by Technology Type
  - 7.4.5.3.2. Market size and forecast, by Indication
  - 7.4.5.3.3. Market size and forecast, by End User
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Market size and forecast, by Technology Type
  - 7.4.5.4.2. Market size and forecast, by Indication
  - 7.4.5.4.3. Market size and forecast, by End User
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Technology Type
  - 7.4.5.5.2. Market size and forecast, by Indication
  - 7.4.5.5.3. Market size and forecast, by End User
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Technology Type
  - 7.4.5.6.2. Market size and forecast, by Indication
  - 7.4.5.6.3. Market size and forecast, by End User
7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Technology Type
- 7.5.3. Market size and forecast, by Indication
- 7.5.4. Market size and forecast, by End User
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Technology Type
  - 7.5.5.1.2. Market size and forecast, by Indication
  - 7.5.5.1.3. Market size and forecast, by End User
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Market size and forecast, by Technology Type
  - 7.5.5.2.2. Market size and forecast, by Indication
  - 7.5.5.2.3. Market size and forecast, by End User
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Market size and forecast, by Technology Type
  - 7.5.5.3.2. Market size and forecast, by Indication
  - 7.5.5.3.3. Market size and forecast, by End User
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Market size and forecast, by Technology Type
  - 7.5.5.4.2. Market size and forecast, by Indication
  - 7.5.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2023

CHAPTER 9: COMPANY PROFILES

9.1. CSL Limited
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. Emergent Bio Solutions Inc.
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
9.3. GlaxoSmithKline Plc.
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. Merck & Co., Inc.
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
9.5. Pfizer
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
9.6. Sanofi
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
9.7. Serum Institute of India Pvt. Ltd.
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. Bavarian Nordic
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
9.9. Zhi Fei Biological
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
9.10. Bharat Biotech
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments

ワクチン市場：技術タイプ別、適応症別、エンドユーザー別：世界の機会分析と産業予測、2024年～2035年

Vaccines Market By Technology Type, By Indication, By End User : Global Opportunity Analysis and Industry Forecast, 2024-2035

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章ワクチン市場：技術タイプ別

第5章ワクチン市場：適応症別

第6章ワクチン市場：エンドユーザー別

第7章ワクチン市場：地域別

第8章競争情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

By Technology Type

By Indication

By End User

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: VACCINES MARKET, BY TECHNOLOGY TYPE

CHAPTER 5: VACCINES MARKET, BY INDICATION

CHAPTER 6: VACCINES MARKET, BY END USER

CHAPTER 7: VACCINES MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

ワクチン市場：技術タイプ別、適応症別、エンドユーザー別：世界の機会分析と産業予測、2024年～2035年

Vaccines Market By Technology Type, By Indication, By End User : Global Opportunity Analysis and Industry Forecast, 2024-2035

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 ワクチン市場：技術タイプ別

第5章 ワクチン市場：適応症別

第6章 ワクチン市場：エンドユーザー別

第7章 ワクチン市場：地域別

第8章 競争情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

By Technology Type

By Indication

By End User

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: VACCINES MARKET, BY TECHNOLOGY TYPE

CHAPTER 5: VACCINES MARKET, BY INDICATION

CHAPTER 6: VACCINES MARKET, BY END USER

CHAPTER 7: VACCINES MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章ワクチン市場：技術タイプ別

第5章ワクチン市場：適応症別

第6章ワクチン市場：エンドユーザー別

第7章ワクチン市場：地域別

第8章競争情勢

第9章企業プロファイル